Free tool
FAERS Monitor: Vanrafia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219208 or its brand name (Vanrafia, Atrasentan Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
101
Serious
30
30% of reports
Hospitalization
14
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective9
- fatigue9
- dizziness6
- nausea6
- peripheral swelling6
- product dose omission issue6
- swelling6
- blood creatinine increased5
- oedema5
- rash5
- renal impairment5
- anaemia4
- fluid retention4
- oedema peripheral4
- proteinuria4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2025 | 46 |
| 2026 | 44 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,058 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| proteinuriaSignal | 4 | 43.8 | 16.8 | 127 |
| oedemaSignal | 5 | 19.2 | 8.2 | 69 |
| fluid retentionSignal | 4 | 16.4 | 6.3 | 44 |
| blood creatinine increasedSignal | 5 | 16.0 | 6.8 | 56 |
| swellingSignal | 6 | 13.4 | 6.1 | 57 |
| renal impairmentSignal | 5 | 12.4 | 5.3 | 42 |
| peripheral swellingSignal | 6 | 8.1 | 3.7 | 31 |
| oedema peripheralSignal | 4 | 6.8 | 2.6 | 15 |
| anaemiaSignal | 4 | 4.4 | 1.7 | 7 |
| product dose omission issueSignal | 6 | 4.2 | 2.0 | 12 |
| dizzinessSignal | 6 | 2.5 | 1.2 | 4 |
| fatigueSignal | 9 | 2.4 | 1.3 | 6 |
| rash | 5 | 2.4 | 1.0 | 3 |
| nausea | 6 | 1.6 | 0.7 | 1 |
| drug ineffective | 9 | 1.4 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.